Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antineoplastic agent |
| gptkbp:approvalYear |
2012
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
J04AK05
|
| gptkbp:brand |
gptkb:Sirturo
|
| gptkbp:CASNumber |
843663-66-1
|
| gptkbp:chemicalFormula |
C32H31BrN2O2
|
| gptkbp:developedBy |
gptkb:Janssen_Pharmaceutica
|
| gptkbp:discoveredBy |
gptkb:Janssen_Pharmaceutica
|
| gptkbp:eliminationHalfLife |
5.5 months
|
| gptkbp:firstBook |
diarylquinoline antimycobacterial
|
| https://www.w3.org/2000/01/rdf-schema#label |
bedaquiline
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits mycobacterial ATP synthase
|
| gptkbp:metabolism |
liver (CYP3A4)
|
| gptkbp:molecularWeight |
555.5 g/mol
|
| gptkbp:pregnancyCategory |
Not recommended
|
| gptkbp:proteinBinding |
>99.9%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
headache QT prolongation hepatotoxicity arthralgia |
| gptkbp:usedFor |
multidrug-resistant tuberculosis
|
| gptkbp:bfsParent |
gptkb:Sirturo
|
| gptkbp:bfsLayer |
8
|